This $799,978 Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) supports the development of "NOMORE", a digitally controlled aerosolized nicotine replacement therapy product. The award aims to advance "NOMORE" from the prototype stage through regulatory approval and into initial human trials. Key planned activities include completing the prototype, conducting proof-of-concept testing, preparing and submitting the pre-IND package, and executing GLP toxicology studies and a feasibility trial. The proposed product is intended to provide a more effective nicotine replacement option for smoking cessation compared to currently approved medications. The award recipient is Predictably Human, Inc., a for-profit organization located in Darien, Connecticut. Successful completion of this fast-track program is expected to position "NOMORE" for further clinical development and commercialization.
Generated 4/1/25, 4:38 AM